Abbott Laboratories (ABT)

NYSE: ABT · IEX Real-Time Price · USD
119.40
+0.71 (0.60%)
At close: Feb 27, 2024, 4:00 PM
119.35
-0.05 (-0.04%)
After-hours: Feb 27, 2024, 7:33 PM EST
0.60%
Market Cap 205.95B
Revenue (ttm) 40.11B
Net Income (ttm) 5.72B
Shares Out 1.74B
EPS (ttm) 3.26
PE Ratio 36.63
Forward PE 25.63
Dividend $2.20 (1.84%)
Ex-Dividend Date Apr 12, 2024
Volume 3,184,580
Open 118.16
Previous Close 118.69
Day's Range 117.83 - 119.50
52-Week Range 89.67 - 120.15
Beta 0.75
Analysts Buy
Price Target 125.27 (+4.92%)
Earnings Date Apr 17, 2024

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1888
Employees 114,000
Stock Exchange NYSE
Ticker Symbol ABT
Full Company Profile

Financial Performance

In 2023, ABT's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.72 billion, a decrease of -17.45%.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $125.27, which is an increase of 4.92% from the latest price.

Price Target
$125.27
(4.92% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What's Next For Abbott Stock After A 6% Rise This Year?

Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a pe...

5 days ago - Forbes

Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott

Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on M...

Other symbols: FDXHONHUMKO
11 days ago - Forbes

Abbott Declares 401st Consecutive Quarterly Dividend

ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.

11 days ago - PRNewsWire

Abbott's heart valve repair device gets FDA advisers' backing

Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or dea...

14 days ago - Reuters

Abbott Laboratories says FDA independent panel votes to approve heart device

Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.

14 days ago - Market Watch

FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U...

14 days ago - PRNewsWire

US FDA staff raises no new concerns about Abbott's heart device

The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients who a...

18 days ago - Reuters

Abbott Labs must face lawsuit over PediaSure height claims

A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinicall...

25 days ago - Reuters

New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again

Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre...

26 days ago - PRNewsWire

Drugmaker Abbott India's Q3 profit rises on strong demand

Pharmaceutical firm Abbott India reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines.

26 days ago - Reuters

Abbott launches protein shake brand to help people on weight-loss drug

Abbott Laboratories said on Wednesday it has launched a new protein shake that would help adults looking to lose weight and maintain their muscle mass.

27 days ago - Reuters

Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed m...

27 days ago - PRNewsWire

4 med tech stocks with improving prognosis for 2024

Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate,...

Other symbols: ISRGJNJSYK
27 days ago - MarketBeat

Jim Cramer just bought Abbott stock: should you too?

A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought...

4 weeks ago - Invezz

Up Just 6% In 2023 Is Medtronic Stock A Better Pick Over Abbott?

Given its better prospects, we believe Medtronic stock (NYSE: MDT) is a better pick than its peer, Abbott stock (NYSE: ABT). Abbott trades at a higher valuation multiple of 4.9x revenues vs.

Other symbols: MDT
4 weeks ago - Forbes

Abbott Laboratories on track for new highs in 2024

Abbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report that was largely as expected, with the ex...

4 weeks ago - MarketBeat

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest ti...

4 weeks ago - PRNewsWire

Once Slowed By Shutdown, Abbott Labs Says Baby Formula Franchise Back Leading U.S. Market

Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”

4 weeks ago - Forbes

Abbott reports solid results for its fiscal Q4

Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter. Why is Abbott stock down on Wednesday?

4 weeks ago - Invezz

Abbott Laboratories Stock Is Down. Earnings, Sales Aren't the Problem.

Abbott, a maker of healthcare products, posted fourth-quarter earnings in line with expectations, and beat sales estimates.

4 weeks ago - Barrons

Abbott Labs' fourth-quarter sales top estimates amid strong medical-device demand

Abbott Laboratories' stock ABT, -0.17% fell 2% premarket on Wednesday after the healthcare-products company reported fourth-quarter sales that topped expectations amid strength in its medical-device a...

4 weeks ago - Market Watch

Abbott's strong medical device sales helps meet quarterly profit expectations

Abbott Laboratories on Wednesday reported a fourth-quarter profit that met Wall Street estimates as strong demand for medical devices offset lower-than-expected sales in its pharmaceuticals unit.

4 weeks ago - Reuters

Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook

Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reported sales decreased 8.1 percent due to anticipated...

4 weeks ago - PRNewsWire

Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses hig...

5 weeks ago - PRNewsWire

Final Trades: Uber, URNM, Abbott Labs and Vertex Pharma

Brenda Vingiello, Sand Hill Global Advisors CIO, Bryn Talkington, Requisite Capital Management managing partner, Jim Lebenthal, Cerity Partners chief equity strategist, and Josh Brown, Ritholtz Wealth...

Other symbols: UBERVRTXURNM
6 weeks ago - CNBC Television